To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
This bill has not become law. Status shown reflects the latest official action.
See what this could mean for your district
Save your district in Account to view district-specific context for this bill.
Bill details
Summary
Introduced in House
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
District impact notes
This bill requires the FDA to inform generic drug applicants about how their products compare to brand-name drugs and to explain any differences. • This policy could matter locally by potentially affecting the availability and pricing of generic medications in the area. • Local healthcare providers and pharmacies may need to adjust their practices based on the updated guidance from the FDA regarding generic drug approvals. • There may be questions about how effectively the FDA can implement these transparency measures without delaying the approval process for new generic drugs. AI-generated from official bill summary and plain-English note; verify with official text.
Related votes
Roll calls that reference this bill in official data.
Primary sources
Official links to verify details. (No interpretation.)
About this data
- OurCongress is non-partisan by design. We do not add political interpretation or advocacy.
- Bill data and official summaries come from GovInfo and Congress.gov. Some bills do not have published summaries yet.
- District impact notes (when shown) are AI-generated from official bill metadata/summaries to improve readability. They are not official government language.
- This page updates automatically via a daily ingestion pipeline.